Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4512 in relapsed/refractory B-cell acute lymphoblastic leukemia
2025-522372-93-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of AZD4512 in acute lymphoblastic leukemia (ALL), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability in Module 1 dose escalation, Maximum tolerated dose and doses to explore in Module 2 and 2 more. Planned start Nov 2025; status: authorised.
02
Drugs
AZD4512
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2025-522372-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522372-93-00.